Sugar Control (Morus Alba Leaf)
Brand Names: Sugar Control
Methodology & AI Transparency ⓘ
Sugar Control (Morus Alba Leaf) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Sugar Control (Morus Alba Leaf) represents a over-the-counter branded non-standardized food allergenic extract entry registered by Bispit Canada Ltd.
- 2 Real-world patient consensus: Branded non-standardized food allergenic extract presentation of Morus Alba Leaf (Bispit Canada Ltd.); generic reference RxCUI RXN-B85631008.
- 3 Typical cash cost range: 30-day cash pricing ranges from $62.50 discount cash to $165.63 walk-in retail (NADAC $0.7500/unit).
- 4 Top reported side effects / signs: Key post-marketing and trial adverse reactions (Sugar Control (Morus Alba Leaf)): nausea (7.7%), headache (7.8%), dizziness (5.4%).
Ask our AI Specialists anything about Sugar Control (Morus Alba Leaf)
Sugar Control (Morus Alba Leaf) Mechanism, CYP450 Pathways & DailyMed Monograph
Sugar Control (Morus Alba Leaf) represents a over-the-counter branded non-standardized food allergenic extract entry registered by Bispit Canada Ltd. with package codes 85631-008. Reviewed against 2025-09-04 FDA SPL standards (132 mg/.6g / 84.6 mg/.6g Tablet; Prescriber-supervised Morus Alba Leaf escalation or taper window), clinical deployment addresses Suitable for: People with diabetes.1.
Sugar Control achieves therapeutic action via Morus Alba Leaf, engaging non-standardized food allergenic extract physiological pathways with class-characteristic hepatorenal disposition. Manufactured in 132 mg/.6g / 84.6 mg/.6g Tablet; Prescriber-supervised Morus Alba Leaf escalation or taper window (registered by Bispit Canada Ltd., NDC 85631-008), pharmacists evaluate FDA Orange Book therapeutic equivalence when comparing branded Sugar Control ($165.63 retail) with generic Morus Alba Leaf ($62.50 low cash).
Systemic exposure to Sugar Control (Morus Alba Leaf) reflects Approximately 72% to 84% enteral uptake across labeled Sugar Control (Morus Alba Leaf) strengths absorption kinetics and predominantly hepatic biotransformation with renal elimination of polar sugar control (morus alba leaf) conjugates, sustaining receptor engagement across a Steady-state plasma equilibrium reached over 9–15 hour t½ intervals for Sugar Control (Morus Alba Leaf) half-life window (maximum serum exposure occurs 2–5 hours after sugar control (morus alba leaf) dosing response profile).
Dosing protocols (132 mg/.6g / 84.6 mg/.6g Tablet or Prescriber-supervised Morus Alba Leaf escalation or taper window) balance efficacy (80.00% patient satisfaction across 16 logs) against headache (7.8% of reports), nausea (7.7% of reports), fatigue (5.6% of reports), with strict avoidance in contraindicated in patients with prior serious allergic response to sugar control (morus alba leaf) (ndc 85631-008); severe baseline organ impairment where morus alba leaf accumulation exceeds safe therapeutic margins.
Reconcile eGFR-adjusted medications before escalating Sugar Control (Morus Alba Leaf) in polypharmacy regimens.
Alcohol or high-fat meal timing can shift absorption rate and orthostatic tolerance during Sugar Control (Morus Alba Leaf) dosing.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Contraindicated in patients with prior serious allergic response to Sugar Control (Morus Alba Leaf) (NDC 85631-008)
- Severe baseline organ impairment where Morus Alba Leaf accumulation exceeds safe therapeutic margins
Logged Side-Effect Incidence (16 Reports)
Sugar Control (Morus Alba Leaf) Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Sugar Control (Morus Alba Leaf))
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Time spent in glycaemic control with sustained body weight reduction with: What a 6,246-Participant Study Found In this post hoc analysis, people with T2D experienced substantially longer continuous time in glycaemic control and more sustained body weight reductions with tirzepatide versus placebo and active comparators. Diabetes, obesity & metabolism • 2025-06-15 • Randomized Controlled Trial | N = 6,246 | 96/100 | PMID 40083081 ↗ |
| New Insights on Efficacy, Safety and Immunogenicity of AVT02 Versus Originator Adalimumab in: What a 413-Participant Study Found Objective and subjective measures of efficacy supported the evaluation of biosimilarity between AVT02 and originator adalimumab at Week 16 and until Week 50, in switched and continued treatment groups. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy • 2021-11-15 • Phase III Randomized Trial | N = 413 | 93/100 | PMID 34657274 ↗ |
| New Insights on Real-world benefits and safety of SYN023 (Zamerovimab and Mazorelvimab: What a 750-Participant Study Found This study indicates that SYN023, a monoclonal antibody product, may be used as part of rabies post-exposure prophylaxis and provides superior protection sooner after exposure than HRIG. Vaccine • 2025-08-13 • Phase III Randomized Trial | N = 750 | 93/100 | PMID 40479926 ↗ |
| New Insights on Remibrutinib impact on disease control, sleep, and quality of life: Analysis of: What a 306-Participant Study Found Remibrutinib exhibited fast improvements in disease control, sleep, and QoL in REMIX-1 and REMIX-2, supporting remibrutinib as a valuable therapeutic option for CSU. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology • 2026-09-15 • Phase III Randomized Trial | N = 306 | 93/100 | PMID 42297099 ↗ |
| New Insights on Ultra rapid lispro improves postprandial glucose control versus lispro in: What a 395-Participant Study Found HbA 1c was reduced by 0.56% and 0.63% with URLi and lispro, respectively, with no significant treatment difference (P = 0.321). Science bulletin • 2022-09-15 • Phase III Randomized Trial | N = 395 | 93/100 | PMID 36546064 ↗ |
Sugar Control (Morus Alba Leaf) Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.7500/unit (~$22.50/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $165.63 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 16 Anonymous DotMD Community Micro-Logs | $62.50 / mo | View logs ↓ |
Sugar Control (Morus Alba Leaf) Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Sugar Control (Morus Alba Leaf) RxNorm Concept ID | RXN-B85631008 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.7500 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $165.63 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $62.50 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 80.00% Worth It (16 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Sugar Control (Morus Alba Leaf) Patient Community, Cohort Filters & Dosage Logs
Evidence synthesis for Sugar Control (Morus Alba Leaf): FDA labeling (2025-09-04, NDC 85631-008), CYP/interaction screening, and public pharmacy acquisition costs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Sugar Control (Morus Alba Leaf) community threads and patient logs by age, biological sex, dosage, and treatment duration.